New REAlease® Fluorochrome Technology available

Releasable antibodies for label-free cells

BERGISCH GLADBACH, February 21, 2019 – The new REAlease® Releasable Antibodies from Miltenyi Biotec are based on the ground-breaking REAlease Fluorochrome Technology and allow for the removal of antibodies after cell sorting in just one step. Sorted cells are label-free to provide maximal flexibility in downstream applications.

Multicolor flow cytometry-based cell sorting is the method of choice for isolating specific cell subsets. However, downstream applications using isolated cells are often limited since fluorescence channels and epitopes are blocked by the antibody-fluorochrome conjugates utilized for the flow sorting process. Miltenyi Biotec’s REAlease® Releasable Antibodies with the REAlease Fluorochrome Technology can be removed from cells after sorting. The resulting unlabeled cells expand the options for downstream applications.   

Benefits of the new REAlease® Releasable Antibodies 

  • Marker epitopes become accessible again for downstream applications (e.g. cell culture experiments and cell analysis). 
  • Fluorescence channels become available again for analysis of relabeled cells (e.g. microscopy applications). 
  • Enables sequential flow sorting cycles for the isolation of specific cell subsets. 
  • Recombinantly engineered for reproducible results. 

An award-winning technology

The REAlease Fluorochrome Technology was awarded with the technology prize at the Pharmaceutical Flow Cytometry & Imaging 2018 conference in Stevenage, UK by the delegates of the European Laboratory Research & Innovation Group (ELRIG). 

Learn more about the new REAlease® Releasable Antibodies and the innovative REAlease Technology.

About Miltenyi Biotec

Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our 30 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has 2,500 employees in 28 countries.
www.miltenyibiotec.com

Miltenyi Biotec Media Contact  
Dr. Anja Kohmann 
Miltenyi Biotec GmbH 
press@miltenyibiotec.de